Latest news with #healthcaretechnology
Medscape
6 days ago
- Health
- Medscape
Does AI Aid Rare Bone Fracture Detection in Children?
TOPLINE: In patients with osteogenesis imperfecta, artificial intelligence (AI) assistance improved the fracture detection accuracy of radiologists from 83.4% to 90.7%. However, radiologists performed better than AI when their standalone performance was considered. METHODOLOGY: In this study, researchers analysed 336 appendicular and pelvic radiographs of 48 children (mean age, 12 years) with genetically confirmed osteogenesis imperfecta. The ground truth was determined by a consensus opinion of two consultant paediatric radiologists who labelled acute and healing fractures with bounding boxes. Seven radiologists independently evaluated anonymised images in two rounds — the first round without AI and the second round with AI assistance. The AI tool provided bounding boxes for suspected fractures but did not distinguish acute from healing fractures. After both rounds were completed, the results from radiologists without AI assistance, radiologists with AI assistance, and the AI alone were compared against the ground truth by calculating the intersection between the bounding boxes. TAKEAWAY: AI demonstrated a per-examination accuracy of 74.8% (95% CI, 65.4%-82.7%), compared with the average radiologist performance of 83.4% (95% CI, 75.2%-89.8%). Radiologists using AI assistance improved their average accuracy per examination to 90.7% (95% CI, 83.5%-95.4%). AI support increased average radiologist per-image accuracy by 7.0% (from 84.6% to 91.6%) and per-fracture accuracy by 3.7% (from 76.3% to 80.0%). Per fracture, AI assistance lowered true and false positives while raising true and false negatives, boosting the accuracy by 3.7%, specificity by 10.0%, and positive predictive value by 7.2%. On average, radiologists changed their per-fracture decisions in 72 instances; 69% of those changes matched the AI's suggestion, and 64% improved accuracy. IN PRACTICE: "In conclusion, the results of this study suggest that AI assistance improves radiologists' performance in diagnosing fractures in children with OI [osteogenesis imperfecta], even if it is not specifically trained for this population," the authors of the study wrote. "Nevertheless, compared to radiologists, the standalone AI performance was worse, thus highlighting potential dangers of implementing the AI tool in an autonomous manner," they added. SOURCE: This study was led by Cato Pauling, University College London, London, England. It was published online on July 07, 2025, in European Radiology. LIMITATIONS: Researchers included repeat examinations from some patients over the study period, which may have introduced bias due to similarities in appearances. This study used only one commercially available AI model, despite multiple products being available in the market. Additionally, the lack of a control group of patients without bone fragility disorder made it challenging to objectively evaluate whether the AI tool performed less accurately in children with osteogenesis imperfecta. DISCLOSURES: This study received funding support from the National Institute for Health and Care Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
16-07-2025
- Business
- Yahoo
ZimVie (ZIMV) Announces the Launch of its RealGUIDE Software Suite and Implant Concierge Service in Japan
ZimVie Inc. (NASDAQ:ZIMV) is one of the best undervalued medical device stocks to buy now. On June 5, ZimVie Inc. (NASDAQ:ZIMV) announced the launch of its RealGUIDE Software Suite and Implant Concierge service in Japan. A medical professional working on a dental implant in an operating room. The launch of the service in the Japenese market provides dentists expanded access to a digital dental implant ecosystem that extends from implant planning to placement and offers vertically integrated, end-to-end solutions. Management reported that the dental implant market opportunity is significant in Japan, and the country is ZimVie Inc.'s (NASDAQ:ZIMV) largest market in the APAC region. RealGUIDE software is the first complete cloud-based solution of its kind, and offers dentists all they need for precise implant planning, restorative design, and surgical guides to deliver time, workflow, and cost efficiencies. Implant Concierge is a virtual outsourcing service that aims to simplify and streamline guided surgery and implant treatment planning. ZimVie Inc. (NASDAQ:ZIMV) manufactures, designs, and distributes medical devices and surgical instruments. The company's operations are divided into the Spine Products and Dental Products segments. While we acknowledge the potential of ZIMV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
National Post
04-07-2025
- Business
- National Post
WELL Health Announces Voting Results for Election of Directors
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general meeting held June 30, 2025 (the ' Meeting '), all of the nominees for election as directors of the Company referred to in its notice of meeting and information circular dated May 28, 2025 for the Meeting were elected. Article content A total of 67,105,724 common shares representing 26.52% of the outstanding common shares of the Company were voted by proxy at the Meeting. Voting results for the election of directors at the Meeting were as follows: Article content Article content Article content The results of other matters considered at the Meeting are reported in the Report of Voting Results as filed on SEDAR+ ( filed on July 4, 2025. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Article content Hamed Shahbazi Article content Chief Executive Officer, Chairman and Director Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
Associated Press
04-07-2025
- Business
- Associated Press
WELL Health Announces Voting Results for Election of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)--Jul 4, 2025-- WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general meeting held June 30, 2025 (the ' Meeting '), all of the nominees for election as directors of the Company referred to in its notice of meeting and information circular dated May 28, 2025 for the Meeting were elected. A total of 67,105,724 common shares representing 26.52% of the outstanding common shares of the Company were voted by proxy at the Meeting. Voting results for the election of directors at the Meeting were as follows: The results of other matters considered at the Meeting are reported in the Report of Voting Results as filed on SEDAR+ ( ) filed on July 4, 2025. WELL HEALTH TECHNOLOGIES CORP. Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: View source version on CONTACT: For further information: Tyler Baba Investor Relations, Manager [email protected] 604-628-7266 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH TECHNOLOGY PRACTICE MANAGEMENT SOFTWARE GENERAL HEALTH SOURCE: WELL Health Technologies Corp. Copyright Business Wire 2025. PUB: 07/04/2025 07:01 AM/DISC: 07/04/2025 07:01 AM
Yahoo
26-06-2025
- Business
- Yahoo
Global Healthcare Technology Leader Selects Kneat
LIMERICK, Ireland, June 26, 2025 (GLOBE NEWSWIRE) -- inc. (TSX: KSI) (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a leading healthcare technology and diagnostics company ('the Company') has signed a multi-year Master Services Agreement with Kneat. The Company, which is headquartered in the United States, employs over 50,000 people and manufactures in more than a dozen countries worldwide. This manufacturer of medical technology, including medical devices and pharmaceutical diagnostics, will use the Kneat Gx platform initially to digitize its Commissioning, Qualification and Validation workflows for facilities, equipment and computer systems at several lead manufacturing sites. "After an extensive evaluation process this global leader selected Kneat to drive efficiency, quality and compliance through greater digitalization of their Validation processes,' said Eddie Ryan, Kneat CEO. 'I'm happy that Kneat will be supporting both new builds and ongoing operations where we are proven to deliver significant business value.' The steady pace of Kneat's strategic customer wins indicates that digital validation is progressively becoming the norm for life sciences companies. The State of Validation 2025 study also supports this trend. The total percentage of organizations surveyed that are either using or planning to use digital validation is now 93 percent, versus 86 percent in the 2024 study. The shift is unsurprising. Done right, digital validation delivers speed to market; trustworthy, scalable compliance; and a foundation to leverage integrated automation and AI-driven innovations in the future. About Kneat Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies show up to 40% reduction in documentation cycle times, up to 20% faster speed to market, and a higher compliance standard. Cautionary and Forward-Looking Statements Except for the statements of historical fact contained herein, certain information presented constitutes 'forward-looking information' within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat's business development activities, the use and implementation timelines of Kneat's software within the customer's validation processes, the ability and intent of the customer to scale the use of Kneat's software within the customer's organization, and the compliance of Kneat's platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor's own risk. For more information visit Contact: Katie Keita, Kneat Investor RelationsP: + 1 902-450-2660 E: investors@ in to access your portfolio
